Skip to main content
新赣江 logo

新赣江 — Investor Relations & Filings

Ticker · 920367 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 389 across all filing types
Latest filing 2026-03-31 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920367

About 新赣江

http://www.xgjyy.com/

Jiangxi Xinganjiang Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical products. The company's portfolio encompasses chemical active pharmaceutical ingredients (APIs), chemical drug preparations, and traditional Chinese medicine (TCM) formulations. Its core product offerings target therapeutic areas such as cardiovascular and cerebrovascular health, digestive system disorders, and nutritional supplementation. Key products include Ginkgo Biloba extract, Vitamin C, and various gastrointestinal medications. By maintaining an integrated value chain that spans from raw material synthesis to finished dosage forms, the company ensures quality control and supply chain efficiency. It focuses on delivering high-quality healthcare solutions through continuous innovation in pharmaceutical manufacturing and formulation technology.

Recent filings

Filing Released Lang Actions
关于召开2026年第一次临时股东会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2026 first extraordinary general meeting (临时股东会) of the company 江西新赣江药业股份有限公司. It details the meeting date, voting methods (including online voting), agenda items for shareholder approval, registration procedures, and other meeting logistics. It does not contain financial statements, audit results, or detailed financial data. It is a formal announcement to shareholders about the meeting and voting process rather than the meeting materials or results themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly Proxy Solicitation & Information Statement (PSI). However, since it is a notice of the meeting and voting arrangements rather than solicitation materials or voting results, it is best classified as a Regulatory Filing (RNS) as a fallback for general regulatory announcements that do not fit other categories. The document length is under 5,000 characters and is primarily an announcement, not a full report or transcript. Hence, the best classification is Regulatory Filings (RNS).
2026-03-31 Chinese
财通证券股份有限公司关于江西新赣江药业股份有限公司使用闲置募集资金进行现金管理的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor’s verification opinion (“核查意见”) by the underwriting institution regarding the target company’s use of idle proceeds for cash management. It is a compliance/regulatory disclosure under exchange rules, not an annual or interim report, not an earnings release, and not a financing announcement per se. It does not itself contain audited financial statements but is an attestation of regulatory compliance. Therefore, it falls into the catch-all Regulatory Filings category (RNS).
2026-03-31 Chinese
关于使用闲置自有资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Jiangxi Xinganjiang Pharmaceutical Co., Ltd. regarding the progress of using idle proprietary funds to purchase financial products. It includes specifics about the amounts, types, counterparties, and terms of the financial products purchased, as well as internal controls and risk disclosures. The document is not a financial report like an annual or interim report, nor is it a regulatory certification or voting result. It is a disclosure about capital usage and investment activities related to the company's own funds. This fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes. The document length is substantial and contains detailed financial data about the investments, supporting this classification with high confidence.
2026-03-23 Chinese
关于江西新赣江药业股份有限公司二级子公司增资暨关联交易的核查意见
Regulatory Filings Classification · 65% confidence The document is a detailed “核查意见” (sponsor’s review opinion) on a related‐party capital increase transaction at a subsidiary, prepared by the sponsoring securities firm under listing rules. It is not an earnings release, proxy, annual/interim report, or management discussion; rather it is a mandatory regulatory disclosure by the sponsor. It does not constitute a standalone audit report or financial supplement but is a specific compliance filing. Therefore it falls under the Regulatory Filings (RNS) category.
2026-03-09 Chinese
第三届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 17th meeting of the third board of directors of Jiangxi Xinganjiang Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and related procedural compliance. The content focuses on board decisions regarding a capital increase in a subsidiary and related party transactions. There is no financial data or comprehensive report content, but rather a summary of board meeting decisions. This fits the definition of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1322 characters), and it is not an announcement of a report publication or a certification letter, so it is not RPA or RNS. Therefore, the classification is MANG with high confidence.
2026-03-09 Chinese
关于二级子公司增资暨关联交易公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a capital increase in a secondary subsidiary and related party transactions. It details the shareholding changes, approval procedures by the board, and the impact of the transaction. It does not contain financial statements or comprehensive financial data but rather focuses on the transaction announcement and related disclosures. The document length is 4227 characters, which is relatively short and typical for an announcement. It is not an annual or interim report, audit report, or earnings release. It is not a call transcript or presentation. The content fits best with a Capital/Financing Update (CAP) as it concerns a capital increase and related party transaction disclosures.
2026-03-09 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.